A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors

Clinical trial NCT07583316 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07583316
Sponsor: Corregene Biotechnology Co., Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Lung Cancer (Locally Advanced or Metastatic)Esophagus Cancer Head and Neck Cancer Hepatocellular Carcinoma (HCC)

Start date: 2026-05-29
Primary completion: 2030-03-30
Enrollment: 192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.